Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryFeb212011	Fate Therapeutics Announces Encouraging Clinical Results and Change in Management Fate Therapeutics announces encouraging clinical results and change in management San Diego, CA – February 21, 2011 – In parallel with announcing encouraging clinical data at the 2011 BMT Tandem Meetings from its ongoing proof-of-concept FT1050 Phase 1b trial, Fate Therapeutics Read All »	View HTML Fate Therapeutics announces encouraging clinical results and change in management 12.6 KB
Toggle SummaryFeb212011	Fate Therapeutics Announces Emerging Data From Proof-Of-Concept FT1050 Clinical Trial and Receives Orphan Drug Designation Encouraging Phase 1b Clinical Data Presented at 2011 BMT Tandem Meetings Read All »	View HTML Fate Therapeutics Announces Emerging Data From Proof-Of-Concept FT1050 Clinical Trial and Receives Orphan Drug Designation 12.6 KB
Toggle SummaryNov042021	Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting FT596 Oral and FT516 Poster Presentations to Highlight Updated Clinical Data for Relapsed / Refractory Lymphoma on Monday, December 13 Company to Host Virtual Investor Event on Tuesday, December 14 SAN DIEGO , Nov. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML
Toggle SummaryDec112017	Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 Stage All Subjects Achieved Day 100 Relapse-free Survival All Incidents of Day 100 Acute GvHD Responded to Steroid Treatment Randomized, Controlled and Double-Blinded Phase 2 Stage of PROTECT Now Enrolling SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML Fate Therapeutics Announces Day 100 Clinical Results from Phase 1 Stage of PROTECT Trial of ProTmune™ and Initiation of Phase 2 Stage 25.6 KB
Toggle SummaryOct182009	Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming Development of Two Week Method for Generating Human Induced Pluripotent Stem Cells with 200-Fold Increase in Yield Read All »	View HTML Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming 11.2 KB
Toggle SummaryJan082021	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO , Jan. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing Read All »	View HTML
Toggle SummaryJun112020	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO , June 11, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing Read All »	View HTML
Toggle SummarySep252018	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares SAN DIEGO , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing of an underwritten public offering of Read All »	View HTML
Toggle SummaryMay272015	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares SAN DIEGO , May 27, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced the closing of an underwritten public offering of Read All »	View HTML Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 147.1 KB
Toggle SummaryDec152017	Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares SAN DIEGO, Dec. 15, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the closing of an underwritten public offering of Read All »	View HTML Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares 378.4 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.